Tags

Type your tag names separated by a space and hit enter

Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Bone. 2009 Dec; 45(6):1059-64.BONE

Abstract

OBJECTIVES

Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This article describes the efficacy, safety, and tolerability of this agent over 8 years.

METHODS

Postmenopausal osteoporotic women having participated in the 5-year efficacy trials SOTI and TROPOS were invited to enter a 3-year open-label extension study. The results presented here focus on patients who received strontium ranelate for 8 years.

RESULTS

At the extension baseline, the population treated for 8 years (n=879; 79.1+/-5.6 years) had femoral neck T-score of -2.61+/-0.71. The cumulative incidences of new vertebral and nonvertebral fractures (13.7% and 12.0%, respectively) over years 6 to 8 were non-statistically different from the cumulative incidences in the first 3 years of the original studies (11.5% and 9.6%). Lumbar spine, femoral neck, and total hip bone mineral density (BMD) increased throughout the 8-year period. Annual relative change in BMD was significant at every visit, except the 8-year visit for femoral neck and total hip BMD. Strontium ranelate was safe and well tolerated over 8 years.

CONCLUSIONS

Long-term treatment with strontium ranelate 2 g/day in postmenopausal osteoporotic women leads to continued increases in BMD at all sites. The data also provide some evidence for a sustained antifracture efficacy.

Authors+Show Affiliations

Department of Public Health Sciences, University of Liège, Liège, Belgium. jyreginster@ulg.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19679207

Citation

Reginster, J Y., et al. "Long-term Treatment of Postmenopausal Osteoporosis With Strontium Ranelate: Results at 8 Years." Bone, vol. 45, no. 6, 2009, pp. 1059-64.
Reginster JY, Bruyère O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone. 2009;45(6):1059-64.
Reginster, J. Y., Bruyère, O., Sawicki, A., Roces-Varela, A., Fardellone, P., Roberts, A., & Devogelaer, J. P. (2009). Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone, 45(6), 1059-64. https://doi.org/10.1016/j.bone.2009.08.004
Reginster JY, et al. Long-term Treatment of Postmenopausal Osteoporosis With Strontium Ranelate: Results at 8 Years. Bone. 2009;45(6):1059-64. PubMed PMID: 19679207.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. AU - Reginster,J Y, AU - Bruyère,O, AU - Sawicki,A, AU - Roces-Varela,A, AU - Fardellone,P, AU - Roberts,A, AU - Devogelaer,J P, Y1 - 2009/08/11/ PY - 2009/05/15/received PY - 2009/07/06/revised PY - 2009/08/01/accepted PY - 2009/8/15/entrez PY - 2009/8/15/pubmed PY - 2010/1/27/medline SP - 1059 EP - 64 JF - Bone JO - Bone VL - 45 IS - 6 N2 - OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This article describes the efficacy, safety, and tolerability of this agent over 8 years. METHODS: Postmenopausal osteoporotic women having participated in the 5-year efficacy trials SOTI and TROPOS were invited to enter a 3-year open-label extension study. The results presented here focus on patients who received strontium ranelate for 8 years. RESULTS: At the extension baseline, the population treated for 8 years (n=879; 79.1+/-5.6 years) had femoral neck T-score of -2.61+/-0.71. The cumulative incidences of new vertebral and nonvertebral fractures (13.7% and 12.0%, respectively) over years 6 to 8 were non-statistically different from the cumulative incidences in the first 3 years of the original studies (11.5% and 9.6%). Lumbar spine, femoral neck, and total hip bone mineral density (BMD) increased throughout the 8-year period. Annual relative change in BMD was significant at every visit, except the 8-year visit for femoral neck and total hip BMD. Strontium ranelate was safe and well tolerated over 8 years. CONCLUSIONS: Long-term treatment with strontium ranelate 2 g/day in postmenopausal osteoporotic women leads to continued increases in BMD at all sites. The data also provide some evidence for a sustained antifracture efficacy. SN - 1873-2763 UR - https://www.unboundmedicine.com/medline/citation/19679207/Long_term_treatment_of_postmenopausal_osteoporosis_with_strontium_ranelate:_results_at_8_years_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(09)01816-X DB - PRIME DP - Unbound Medicine ER -